Pathophysiology, Diagnosis, and Multidisciplinary Management of Bone Metastases

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 950

Special Issue Editor


E-Mail Website
Guest Editor
Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, 80125 Naples, Italy
Interests: magnetic resonance; oncologic radiology; abdominal radiology; bone metastases; lung cancer; breast cancer; colo-rectal cancer; whole-body diffusion-weighted imaging; whole-body MRI; contrast media; computed tomography
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Bone metastasis is prevalent among epithelial tumors, particularly in the Western world, with prostate, lung, and renal cancers being prominent sources. Normal bone function relies on a delicate balance and collaboration between osteoblasts and osteoclasts that cooperate to ensure the continuous remodeling of bone tissue.
Bone lesions can lead to functional limitations, causing a reduction in patients’ mobility and leading to secondary complications, such as pathological fractures, spinal cord compression, hypercalcemia, or bone marrow suppression. Pain is the most common symptom of bone metastases; it can be intense and exacerbated by movements, even minor ones, such as coughing, moving limbs, or turning in bed, severely compromising a patient’s quality of life.
This Special Issue aims to bring specialists together to delve into this complex landscape, addressing the challenges posed by bone metastases across various disciplines

Dr. Alfonso Reginelli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • magnetic resonance
  • oncologic
  • radiotherapy
  • oncologic diagnostics
  • bone metastases
  • lung cancer
  • breast cancer
  • prostate cancer
  • whole-body diffusion-weighted imaging
  • whole-body MRI

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

32 pages, 1656 KiB  
Review
From Bench to Bedside: Translational Approaches to Cardiotoxicity in Breast Cancer, Lung Cancer, and Lymphoma Therapies
by Valerio Nardone, Dafne Ruggiero, Maria Giovanna Chini, Ines Bruno, Gianluigi Lauro, Stefania Terracciano, Angela Nebbioso, Giuseppe Bifulco, Salvatore Cappabianca and Alfonso Reginelli
Cancers 2025, 17(7), 1059; https://doi.org/10.3390/cancers17071059 - 21 Mar 2025
Viewed by 591
Abstract
Cardiotoxicity represents a critical challenge in cancer therapy, particularly in the treatment of thoracic tumors, such as lung cancer and lymphomas, as well as breast cancer. These malignancies stand out for their high prevalence and the widespread use of cardiotoxic treatments, such as [...] Read more.
Cardiotoxicity represents a critical challenge in cancer therapy, particularly in the treatment of thoracic tumors, such as lung cancer and lymphomas, as well as breast cancer. These malignancies stand out for their high prevalence and the widespread use of cardiotoxic treatments, such as chemotherapy, radiotherapy, and immunotherapy. This work underscores the importance of preclinical models in uncovering the mechanisms of cardiotoxicity and developing targeted prevention and mitigation strategies. In vitro models provide valuable insights into cellular processes, enabling the observation of changes in cell viability and function following exposure to various drugs or ionizing radiation. Complementarily, in vivo animal models offer a broader perspective, allowing for evaluating of both short- and long-term effects and a better understanding of chronic toxicity and cardiac diseases. By integrating these approaches, researchers can identify potential mechanisms of cardiotoxicity and devise effective prevention strategies. This analysis highlights the central role of preclinical models in advancing knowledge of cardiotoxic effects associated with common therapeutic regimens for thoracic and breast cancers. Full article
Show Figures

Figure 1

Back to TopTop